[Press Alert] XENOTHERA announces the efficacy of its XAV-19 antibody against the BQ.1.1variant.
December 19, 2022. # Download our press alert (english version) # Télécharger...
More[Press Release] XAV-19: end of EUROXAV clinical trial and positive trends for the XENOTHERA antibody.
December 16,2022. # Download our press release (english version) # Télécharger notre...
More[Newsletter] XENONEWS
November 2022. >> Official XENOTHERA’s newsletter /Lettre d’information officielle de XENOTHERA <<...
More[Press Information] Orphan designation by the European Medicines Agency for LIS1, the transplant induction therapy from XENOTHERA
July 11th, 2022. # Download our press information (english version) # Télécharger...
More[Press Alert] Safety and efficacy results of LIS1
June 2022. # Download our press information (english version) # Télécharger notre...
More[Press Information] XENOTHERA presents LIS1 results at the American Transplant Congress (ATC) in Boston
May 2022. # Download our press information (english version) # Télécharger notre...
More[ Press Information ] APPOINTMENTS
April 2022. # Download our press information (english version) # Télécharger notre...
More[Press information] XENOTHERA announces the continuation of development of its anti-SARS-CoV-2 antibody.
January 2022. # Download our press information (english version) # Télécharger notre...
More[Press Alert] Omicron Variant : positive results for XENOTHERA's XAV-19 antibody
December 2021. # Download our press information (english version) # Télécharger notre...
More